CDK2 and neoplasm: CFI-400945 treatment causes polyploidy, tumor growth inhibition and apoptosis; synergizes with CDK2 (cyclin-dependent kinase 2) inhibitor seliciclib; leads to radiosensitization in non-small cell lung cancer cell lines and enhances radiation-induced tumor growth delay in xenograft models.